Sorafenib and Erlotinib in Treating Patients With Metastatic or Unresectable Solid Tumors
- Conditions
- Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- Registration Number
- NCT00126620
- Lead Sponsor
- University Health Network, Toronto
- Brief Summary
RATIONALE: Sorafenib and erlotinib may stop the growth of tumor cells by blocking blood flow to the tumor and by blocking some of the enzymes needed for cell growth.
PURPOSE: This phase I trial is studying the side effects and best dose of sorafenib and erlotinib in treating patients with metastatic or unresectable solid tumors.
- Detailed Description
OBJECTIVES:
Primary
* Determine the maximum tolerated dose and recommended phase II dose of sorafenib and erlotinib in patients with metastatic or unresectable solid tumors.
Secondary
* Determine the optimal biologically effective dose of this regimen that will lead to hypophosphorylation of epidermal growth factor receptor (EGFR), ERK, Akt, and vascular endothelial growth factor receptor (VEGFR), and inhibition of angiogenesis and apoptosis with tolerable toxicity in these patients.
* Correlate the pharmacokinetic profiles of this regimen with toxicity and biological activity in these patients.
* Determine, preliminarily, the antitumor activity of this regimen in these patients.
* Correlate phosphorylation status of EGFR, ERK, Akt, and VEGFR with antitumor activity of this regimen in these patients.
OUTLINE: This is a multicenter, open label, non-randomized, dose-escalation study.
Patients receive oral sorafenib alone once or twice daily on days -6 to 0\*. Patients then receive oral sorafenib once or twice daily and oral erlotinib once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
NOTE: \*Not considered part of course 1; considered a "run-in" period only.
Cohorts of 3-6 patients receive escalating doses of sorafenib and erlotinib until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. An additional 10 patients are treated at the MTD.
After completion of study treatment, patients are followed at 4 weeks and then at least annually thereafter.
PROJECTED ACCRUAL: A total of 16-28 patients will be accrued for this study within 5-14 months.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 17
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description OSI-774 erlotinib) and Bay 43-9006 (Sorafenib) sorafenib tosylate Sorafenib administered alone for a 1-week run-in period, and then both drugs e given together continuously, with every 28 days considered as a cycle. Three dose levels assessed. OSI-774 erlotinib) and Bay 43-9006 (Sorafenib) erlotinib hydrochloride Sorafenib administered alone for a 1-week run-in period, and then both drugs e given together continuously, with every 28 days considered as a cycle. Three dose levels assessed.
- Primary Outcome Measures
Name Time Method Maximum tolerated dose and recommended phase II dose 28 days
- Secondary Outcome Measures
Name Time Method Pharmacodynamic outcomes Pre study and cycle 1 Correlation of EGFR, AKT, ERK and VEGFR with antitumor activity If responses or prolonged stable disease are observed EGFR activating mutations, gene amplification status, EGFR intron 1 polymorphism if responses or prolonged disease stabilization are seen If responses or prolonged stable disease are observed Pharmacokinetic outcomes Pre-study, cycle 1 and cycle 2 Antitumor activity Every 8 wks
Trial Locations
- Locations (2)
Princess Margaret Hospital
🇨🇦Toronto, Ontario, Canada
Margaret and Charles Juravinski Cancer Centre
🇨🇦Hamilton, Ontario, Canada